TORONTO, Dec. 5, 2012 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for
patients with septic shock, today announced that 76 patients have been
randomized into its EUPHRATES trial and have been followed for 28 day
mortality assessment in accordance with the trial's protocol.
A meeting of the trial's Data and Safety Monitoring Board (DSMB) has
been scheduled for the end of January, 2013. The DSMB will evaluate the
interim data to determine if there are any safety concerns and if they
are satisfied with the study conduct. Spectral anticipates that it will
disclose the details of this interim analysis by the end of February,
"We achieved this enrollment milestone for our first planned interim
analysis due to the commitment of our site investigators and the
trial's steady patient enrollment rate," said Dr. Paul Walker,
President and CEO of Spectral Diagnostics. "We are looking forward to
the results of this analysis on the trial's conduct and safety. Our
second planned interim analysis will provide valuable information to
guide the completion of this Phase III trial."
The second interim analysis will occur after 184 randomized patients
have been followed for 28 days. At the second analysis, the DSMB will
advise Spectral on the trial's safety, efficacy or futility, with
stopping rules in place for efficacy and futility. A sample size
recalculation will be done if necessary. Management remains on track to
disclose information from the second interim analysis in the first
quarter of 2014.
Spectral's EUPHRATES trial continues to track at a higher-than-predicted
composite mortality rate, which is the combined mortality rate for the
treated and the placebo groups (approximately 35% compared to a
predicted rate of 27.5%). The higher composite mortality rate suggests
that patients who are most at risk and most likely to benefit from
treatment are being randomized into the trial. Spectral continues to
initiate sites in Canada and the United States into the EUPHRATES trial
in order to meet recruitment targets. The trial is currently targeted
to enroll 306 evaluable patients at up to 60 North American sites.
Contingent on maintaining current enrolment rates and timely site start
ups, the trial should be fully enrolled by the end of 2014.
EUPHRATES is a randomized, double-blind controlled clinical trial that
compares standard of care versus standard of care and Toraymyxin,
directed by Spectral's EAA™ Endotoxin Activity Assay. Spectral's EAA™
is the only FDA-cleared diagnostic for the risk of developing sepsis.
The target population for EUPHRATES is critically ill patients with
septic shock and endotoxemia (as measured by the EAA™). The trial's
primary endpoint is 28-day mortality.
Toraymyxin has been approved for therapeutic use in Japan and Europe,
and has been used safely and effectively in more than 100,000 patients
to date. In March 2009, Spectral obtained the exclusive development and
commercial rights in the U.S. for Toraymyxin, and in November, 2010
signed an exclusive distribution agreement for this product in Canada.
More than 250,000 patients are diagnosed with severe sepsis and septic
shock in North America each year, representing a greater than $1
billion market opportunity for Spectral.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product for the treatment of septic shock. Toraymyxin is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream. Directed by the Company's Endotoxin
Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of
developing sepsis, Spectral's EUPHRATES trial is the world's first
theranostics trial in the area of sepsis.
Spectral is listed on the Toronto Stock Exchange under the symbol SDI,
and on the OTQ QX under the symbol DIAGF. For more information please
Information in this news release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the future outlook of Spectral and
anticipated events or results, are assumptions based on beliefs of
Spectral's senior management as well as information currently available
to it. While these assumptions were considered reasonable by Spectral
at the time of preparation, they may prove to be incorrect. Readers are
cautioned that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business
opportunities in the biomedical industry, the granting of necessary
approvals by regulatory authorities as well as general economic, market
and business conditions, and could differ materially from what is
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
SOURCE: Spectral Diagnostics Inc.
For further information:
Executive Vice President and CFO
416-626-3233 ext. 2200
416-815-0700 ext. 225